



(51) International Patent Classification:

C07D 473/32 (2006.01) A61K 31/52 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2009/045603

(22) International Filing Date:

29 May 2009 (29.05.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/057,559 30 May 2008 (30.05.2008) US

(71) Applicants (for all designated States except US):

GENENTECH, INC. [US/US]; 1 Dna Way, South San Francisco, CA 94080 (US). **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CASTANEDO, Georgette** [US/US]; Genentech, Inc., 1 Dna Way, South San Francisco, CA 94080 (US). **CHUCKOWREE, Irina** [MU/CH]; F. Hoffmann-la Roche Ag, Grenzacherstrasse 124, CH-4070 Basel (CH). **FOLKES, Adrian** [GB/CH]; F. Hoffmann-la Roche Ag, Grenzacherstrasse 124, CH-4070 Basel (CH). **SUTHERLIN, Daniel, P.** [US/US]; Genentech, Inc., 1 Dna Way, South San Francisco, CA 94080 (US). **WAN, Nan Chi** [GB/CH]; F. Hoffmann-la Roche Ag, Grenzacherstrasse 124, CH-4070 Basel (CH).(74) Agents: **ANDRUS, Alex** et al.; GENENTECH, INC., 1 Dna Way, Ms-49, South San Francisco, CA 94080 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE




Figure 1

(57) **Abstract:** Purine compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for *in vitro*, *in situ*, and *in vivo* diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.